Please enter a valid ZIP code
  • Abshire T, Kenet G. Safety update on the use of recombinant factor VIIa and the treatment of congenital and acquired deficiency of factor VIII or IX with inhibitors. Haemophilia. 2008;14(5):898-902.

  • Brackmann H-H, Effenberger W, Hess L, Schwaab R, Oldenburg J. Immune tolerance induction: a role for recombinant activated factor VII (rFVIIa)? Eur J Haematol. 1998;61(suppl 63):18-23.

  • Butler RB, Crudder SO, Riske B, Toal S. Basic Concepts of Hemophilia: A Self-Study and Planning Workbook for Families With a New Diagnosis of Hemophilia. Washington, DC: Centers for Disease Control and Prevention, US Department of Health and Human Services; 2007.

  • Bysted BV, Scharling B, Møller T, Hansen BL. A randomized, double-blind trial demonstrating bioequivalence of the current recombinant activated factor VII formulation and a new robust 25˚C stable formulation. Haemophilia. 2007;13(5):527-532.

  • Collins PW, Hirsch S, Baglin TP, et al; for UK Haemophilia Centre Doctors’ Organisation. Acquired hemophilia A in the United Kingdom: a 2-year national surveillance study by the United Kingdom Haemophilia Centre Doctors’ Organisation. Blood. 2007;109(5):1870-1877.

  • Collins PW, Percy CL. Advances in the understanding of acquired haemophilia A: implications for clinical practice. Br J Haematol. 2010;148(2):183-194.

  • Data on file. Novo Nordisk Inc; Princeton, NJ.

  • FEIBA NF [package insert]. Westlake Village, CA: Baxter Healthcare Corporation; 2011.

  • Hensyl WR, ed. Stedman’s Medical Dictionary. 25th ed. Baltimore, MD: Williams & Wilkins; 1990.

  • Hoffman M, Monroe DM III. A cell-based model of hemostasis. Thromb Haemost. 2001;85(6):958-965.

  • Huth-Kühne A, Baudo F, Collins P, et al. International recommendations on the diagnosis and treatment of patients with acquired hemophilia A. Haematologica. 2009;94(4):566-575.

  • Ingerslev J, Knudsen L, Hvid I, Tange MR, Fredberg U, Sneppen O. Use of recombinant factor VIIa in surgery in factor-VII-deficient patients. Haemophilia. 1997;3(3):215-218.

  • Ingerslev J, Kristensen HL. Clinical picture and treatment strategies in factor VII deficiency. Haemophilia. 1998;4(1):689-696.

  • Johannessen M, Andreasen RB, Nordfang O. Decline of factor VIII and factor IX inhibitors during long-term treatment with NovoSeven®. Blood Coagul Fibrinolysis. 2000;11(3):239-242.

  • Kessler CM, Acs P, Mariani G. Acquired disorders of coagulation: the immune coagulopathies. In: Colman RW, Marder VJ, Clowes AW, George JN, Goldhaber SZ, eds. Hemostasis and Thrombosis: Basic Principles and Clinical Practice. 5th ed. Philadelphia, PA: Lippincott Williams & Wilkins; 2006:1061-1084.

  • Konkle BA. Clinical approach to the bleeding patient. In: Colman RW, Marder VJ, Clowes AW, George JN, Goldhaber SZ, eds. Hemostasis and Thrombosis: Basic Principles and Clinical Practice. 5th ed. Philadelphia, PA: Lippincott Williams & Wilkins; 2006:1147-1158.

  • Levesque H, Collins P, Baudo F, et al. Acquired haemophilia: descriptive data of the European acquired haemophilia registry (EACH2) [poster PP-WE-604]. J Thromb Haemost. 2009;7(suppl 2):831-832.

  • Luck JV, Silva M, Rodriguez-Merchan EC, Ghalambor N, Zahiri CA, Finn RS. Hemophilic arthropathy. J Am Acad Orthop Surg. 2004;12(4):234-245.

  • Lusher JM, Roberts HR, Davignon G, et al; and rFVIIa Study Group. A randomized, double-blind comparison of two dosage levels of recombinant factor VIIa in the treatment of joint, muscle and mucocutaneous haemorrhages in persons with haemophilia A and B, with and without inhibitors. Haemophilia. 1998;4(6):790-798.

  • McVey JH, Boswell E, Mumford AD, Kemball-Cook G, Tuddenham EGD. Factor VII deficiency and the FVII mutation database. Hum Mutat. 2001;17(1):3-17.

  • NovoSeven® RT [package insert]. Princeton, NJ: Novo Nordisk Inc; 2012.

  • Perry DJ. Factor VII deficiency. Br J Haematol. 2002;118(3):689-700.

  • Roberts HR, Escobar MA. Less common congenital disorders of hemostasis. In: Kitchens CS, Alving BM, Kessler CM, eds. Consultative Hemostasis and Thrombosis. 2nd ed. Philadelphia, PA: Saunders Elsevier; 2007:61-79.

  • Shapiro AD, Gilchrist GS, Hoots WK, Cooper HA, Gastineau DA. Prospective, randomised trial of two doses of rFVIIa (NovoSeven) in haemophilia patients with inhibitors undergoing surgery. Thromb Haemost. 1998;80(5):773-778.

  • Srivastava A, Brewer AK, Mauser-Bunschoten EP, et al; Treatment Guidelines Working Group on behalf of the World Federation of Hemophilia. Guidelines for the management of hemophilia. Haemophilia. 2013;19(1):e1-e47.

  • Venes D, Thomas CL, eds. Taber’s® Cyclopedic Medical Dictionary. 19th ed. Philadelphia, PA: F.A. Davis Company; 2001.

Indications and Usage

NovoSeven® RT (Coagulation Factor VIIa [Recombinant]) is used for:

Important Safety Information


Warnings and Precautions

Side Effects

Use with Other Drugs

Please click here for NovoSeven® RT Prescribing Information and Instructions for Use.

You are encouraged to report negative side effects of prescription drugs to the FDA. Visit,
or call 1-800-FDA-1088.

NovoSeven® RT is a prescription medicine. Novo Nordisk provides patient assistance for those who qualify. Please call 1-877-NOVO-777 (1-877-668-6777) to learn more about Novo Nordisk assistance programs.